Australian based contract research organisation specialising in neuroscience and beyond
- Epilepsy
- Migraine
- Huntington’s
- Multiple sclerosis
- Neuromuscular
- Neurosurgery
- Parkinson’s
- Stroke
- psychedelics
- Oncology Tracers
- Immunology
- Ophthalmology
- Endocrinology
- COVID-19
- Devices
- Diagnostics
- Pain
- Mental Health
- alzheimer's
- Dementia
- spinal cord injury
- Paediatric Diseases
- Psychotic Disorders
Our expertise
NTA is one of the few CRO’s globally that specialises in CNS projects. We also work in other therapeutic areas, which currently include oncology, psychology, infectious diseases, rare paediatric disease, immunology, devices, endocrinology, and COVID-19. NTA supports pharmaceutical, biotechnology, cell therapy and device companies to undertake their phase I-IV clinical trials according to global regulatory standards, including the TGA, FDA and EMA.
The Australian advantage
Choosing Australia for your clinical research offers very distinct advantages. Australia offers the world’s most attractive R&D cash benefit and an expeditious regulatory environment. You can recover up to 43.5 cents for every dollar you spend on R&D; start your trials without having an IND; and achieve study site start-up within 5-6 weeks because of the TGA’s system of deferment to the Institutional Ethics Committees for study approval.
Our unique network
NTA is a subsidiary of The Florey Institute of Neuroscience and Mental Health, the largest brain research institute in the southern hemisphere, which facilitates a unique professional network. NTA has direct access to therapeutic disease specialists, key opinion leaders and clinical trial sites that collectively enable us to deliver quality clinical trial services with strong recruitment outcomes.
Contact us
Call our team on +61 3 7038 0880 or submit the contact form below.